drugset / Trial / NCT02016235

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

NCT02016235 ↗

Phase 1/2 Completed 30 enrolled Mayo Clinic
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Timeline

Start
2014-09
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Subject phosphate Unknown 250 mg Oral

Indications